While specific treatment options such as endocrine therapy or targeted antibodies are available for luminal-like and human epidermal growth factor receptor-2 (HER2)-positive BC, chemotherapy has historically been the only systemic treatment option for triple-negative breast cancer (TNBC) [3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.